BMBrenda Stefania Pérez Mahecha

Brenda Stefania Pérez Mahecha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brenda Stefania Pérez Mahecha has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of intestinal parasitism in preschool and school children in Colombia: Systematic review and meta‐analysis

    by Fredy A. Pazmiño, Andrés Felipe Mora‐Salamanca, Brenda Stefania Pérez Mahecha, Esteban Javier Pérez Moreno, Mario J. Olivera, Angelica Knudson Ospina, Myriam Consuelo López

    Objective: Intestinal parasitic infections (IPIs) are a public health challenge in developing countries such as Colombia, causing anaemia and delayed growth and development in children. We aimed to estimate the geographical and prevalence trend of IPIs in the last 30 years in school and preschool children in Colombia.Methods: We conducted a systematic review and meta‐analysis. We identified potential manuscripts through PubMed, EMBASE, Web of Science, LILACS, Scielo and Google Scholar on the IPIs prevalence in school and preschool children in Colombia. Articles included in the qualitative analysis were published between 1990 and 2020 in English or Spanish and met the inclusion criteria. Subsequently, a random‐effects meta‐analysis, a meta‐regression and a trend analysis were performed.Results: We identified 2292 articles; 109 were included in the qualitative review, and 79 articles were included in the meta‐analysis. The estimated IPI prevalence was 55% (95% CI: 48–63). By age group, the prevalence in preschool children was 37% (95% CI: 26–49) and 66% (95% CI: 52–78) in schoolchildren. The prevalence by region was heterogeneous, with the Amazon being the highest (69%) and the Santanderes the lowest (28%). In the last 20 years, the prevalence of helminthiasis has decreased (from 64.66% in 1990–1995 to 22.09% in 2016–2020).Conclusion: The prevalence of IPIs is high (>30%) in three of the seven regions in Colombia. Biannual administration of mass deworming in schoolchildren is recommended in the Amazon region. Public policies aiming to control IPIs should be reinforced. Further prevalence studies should include Cesar, Guaviare, Vichada and Vaupés, where the epidemiology of IPIs is unknown.Sustainable Development Goals: Good health and wellbeing, clean water and sanitation, sustainable cities and communities.


  • Efectos de Bloqueadores del Receptor de Angiotensina II e inhibidores de la Enzima Convertidora de Angiotensina en COVID-19: Una revisión narrativa de la literatura

    by Juan David Muñoz Loaiza, Heitmar Santiago Infante, Brenda Stefanía Pérez Mahecha, Juan Esteban Herrera Cardona, David Ricardo Salamanca

    Introduction: An outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is currently affecting worldwide. The association between this virus and the upregulation of Angiotensin-Converting Enzyme 2 (ACE2) has been suggested as a potential as an important factor in the development of Coronavirus Disease- 19 (COVID-19). Objective: To describe the relationship between some antihypertensive treatments and COVID-19. Methods: A research was conducted with the components of the PIO (Population, Intervention, Outcomes) strategy, including the literature of the last 20 years available in central PubMed, Web of Science, Scopus, and Embase databases. All relevant articles that assessed the epidemiological relationship between SARS-CoV-2 and hypertension, the treatment and outcomes of the patients who have this comorbidity, as well as the relationship between the RAA axis and COVID-19 were included in the analysis. Results: A total of 292 items were found in the databases. After a thorough analysis, 17 papers were selected, including in vitro and in vivo tests, clinical trials, and epidemiological studies related to the topic analyzed. Conclusion: Due to the systemic benefits of antihypertensive drugs targeting the RAA axis, and the lack of evidence of these treatments being a risk factor, It is not recommended to withdraw these medications from hypertensive patients infected with SARS-CoV 2, unless there is a clinical indication.